Insider and congress filings

Biogen Inc. (BIIB)

NASDAQ · Healthcare · 297 insider transactions · 126 congress trades · last filed 18 days agoS&P 500

4
Open-market insider filings shown
2d
Median delay on the insider filings, in business days
within the two business day rule
1 buy·3 sells
Purchases and sales in the filings shown
Get a push when an insider at Biogen Inc. trades.

Free on iOS and Android.

About Biogen Inc.

from the company's filings and listing, as of Oct 22, 2026
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Christopher A. Viehbacher
Employees
7,500
Listed since
Sep 17, 1991
Market value
$35.6B
Price to earnings (12 mo)
42.4
Net income per share, as reported (12 mo)
$5.65
Dividend yield
-

www.biogen.com

Company news

1 article · newest first
HeadlineSourceDate
Biogen presents 52-week litifilimab data in cutaneous lupus erythematosusParticipants who switched from placebo to litifilimab at Week 24 showed a rapid onset of effect as early as four weeks.Company releaseOct 2, 2026

Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover

Earnings

6 reported quarters · next on Oct 28, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Jul 29, 2026$3.60$2.94$2.7B$2.5BEPS beatRevenue beat
Q1 FY2026reported Apr 29, 2026$3.57$3.05$2.5B$2.3BEPS beatRevenue beat
Q4 FY2025reported Feb 6, 2026$1.99$1.63$2.3B$2.2BEPS beatRevenue beat
Q3 FY2025reported Oct 30, 2025$4.81$3.88$2.5B$2.3BEPS beatRevenue beat
Q2 FY2025reported Jul 31, 2025$5.47$3.90$2.6B$2.3BEPS beatRevenue beat
Q1 FY2025reported May 1, 2025$3.02$2.90$2.4B$2.2BEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 28, 2026
ExecutiveSalaryStock awardsOtherTotal
Christopher A. ViehbacherPresident and Chief Executive Officer$1.7M$18.4M$3.5M$23.6M
Susan H. AlexanderExecutive Vice President, Chief Legal Officer$1.0M$5.8M$1.3M$8.1M
Nicole C.Murphy Head of Pharmaceutical Operations and Technology$909K$5.6M$1.1M$7.6M
Priya A.Singhal Head of Development$930K$5.6M$1.1M$7.6M
Robin C. KramerExecutive Vice President and Chief Financial Officer$760K$4.2M$873K$5.8M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
FMR LLC$3.9B18,217,239+42.2%12.33%
BlackRock, Inc.$3.5B15,985,736+0.1%10.82%
Primecap Management Co$3.3B15,154,606+2.7%10.26%
Vanguard Capital Management LLC$2.1B9,651,117+1.2%6.53%
State Street Corp$1.6B7,344,327+2.5%4.99%
Vanguard Portfolio Management LLC$1.4B6,604,936+1.1%4.47%
Geode Capital Management, LLC$957.9M4,449,295+2.5%3.01%
Wellington Management Group LLP$673.6M3,117,469+5.3%2.11%
Norges Bank$557.4M2,580,033New1.75%
Morgan Stanley$521.0M2,411,271+11.1%1.63%
AQR Capital Management LLCCliff Asness$416.9M1,936,859+0.7%1.31%
JPMorgan Chase & Co.$394.9M1,823,140-9.6%1.23%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Tracked fund managers holding BIIB

2 managers
ManagerValueSharesShare of book
Alyeska Investment Group$201.4M932,3740.5%
Perceptive AdvisorsJoseph Edelman$59.7M276,1730.9%

2 of the 97 fund managers we track list BIIB shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Know when the next BIIB filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

4 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Lloyd MinorDirectorSold · scheduled593$200.96$119KAug 4, 2026filed Aug 5, 20261d
Lloyd MinorDirectorSold · scheduled593$203.34$121KAug 3, 2026filed Aug 5, 20262d
Nicole MurphyHead of Pharm Ops and TechBought3$195.03$585Feb 12, 2026filed Feb 17, 20262d
Priya SinghalHead of DevelopmentSold · scheduled2,660$199.83$532KFeb 9, 2026filed Feb 10, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Sean GodboutChief Accounting OfficerStock award985Oct 1, 2026
Sean GodboutChief Accounting OfficerTax withholding8Oct 2, 2026
Sean GodboutChief Accounting OfficerOption exercise27Oct 2, 2026
Michael PariniChief Legal OfficerStock award7,405Sep 1, 2026
Maria C. FreireDirectorStock award2,005Jun 9, 2026
Lloyd MinorDirectorStock award1,505Jun 9, 2026
Menelas N. PangalosDirectorOption exercise2,370Jun 9, 2026
Menelas N. PangalosDirectorStock award1,505Jun 9, 2026
Monish D. PatolawalaDirectorStock award1,505Jun 9, 2026
Susan LangerDirectorStock award1,505Jun 9, 2026
Jesus B. MantasDirectorStock award1,505Jun 9, 2026
Eric K. RowinskyDirectorStock award1,505Jun 9, 2026
Stephen A. SherwinDirectorStock award1,505Jun 9, 2026
William A. HawkinsDirectorStock award1,505Jun 9, 2026
Adam KeeneyHead of Corporate DevelopmentTax withholding455May 1, 2026
Adam KeeneyHead of Corporate DevelopmentOption exercise939May 1, 2026
Sean GodboutChief Accounting OfficerTax withholding54Apr 1, 2026
Sean GodboutChief Accounting OfficerOption exercise181Apr 1, 2026
Susan H. AlexanderEVP Chief Legal OfficerStock award8,450Feb 13, 2026
Sean GodboutChief Accounting OfficerStock award1,800Feb 13, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in BIIB

20 disclosures of 126 on record · median 26d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Maria Elvira SalazarStockSale$1,001 - $15,000+10.8%After the saleS&P 500 -1.2% · +11.9 pts vs S&P 500Sep 24, 2026Oct 7, 202613d
Kevin HernStockSale$1,001 - $15,000+17.9%After the saleS&P 500 -1.0% · +18.9 pts vs S&P 500Aug 18, 2026Sep 1, 202614d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+36.4%S&P 500 +19.8% · +16.5 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Maria Elvira SalazarStockSale$15,001 - $50,000+32.8%After the saleS&P 500 +0.1% · +32.7 pts vs S&P 500Jun 2, 2026Jul 7, 202635d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+28.3%S&P 500 +3.0% · +25.3 pts vs S&P 500Jun 5, 2026Jul 2, 202627d
Ro KhannaStockPurchase$1,001 - $15,000+29.9%S&P 500 +2.8% · +27.1 pts vs S&P 500May 15, 2026Jun 9, 202625d
Ro KhannaStockSale$1,001 - $15,000+27.3%After the saleS&P 500 +1.3% · +26.0 pts vs S&P 500May 27, 2026Jun 9, 202613d
Maria Elvira SalazarStockPurchase$50,001 - $100,000+26.6%S&P 500 +2.8% · +23.8 pts vs S&P 500May 11, 2026Jun 8, 202628d
Maria Elvira SalazarStockPurchase$1,001 - $15,000+26.6%S&P 500 +2.8% · +23.8 pts vs S&P 500May 11, 2026Jun 8, 202628d
Maria Elvira SalazarStockPurchase$1,001 - $15,000+25.8%S&P 500 +2.9% · +22.8 pts vs S&P 500May 12, 2026Jun 8, 202627d
Ro KhannaStockSale$1,001 - $15,000+42.1%After the saleS&P 500 +10.8% · +31.4 pts vs S&P 500Apr 13, 2026May 11, 202628d
Ro KhannaStockSale$1,001 - $15,000+24.6%After the saleS&P 500 +10.0% · +14.6 pts vs S&P 500Feb 6, 2026Mar 9, 202631d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+39.4%S&P 500 +9.8% · +29.6 pts vs S&P 500Jan 30, 2026Feb 13, 202614d
Ro KhannaStockPurchase$1,001 - $15,000+42.3%S&P 500 +9.5% · +32.8 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
Ro KhannaStockPurchase$1,001 - $15,000+83.4%S&P 500 +17.8% · +65.6 pts vs S&P 500Aug 26, 2025Sep 9, 202514d
Ro KhannaStockSale$1,001 - $15,000+93.7%After the saleS&P 500 +27.8% · +65.9 pts vs S&P 500May 19, 2025Jun 10, 202522d
Robert BresnahanStockPurchase$1,001 - $15,000+102.7%S&P 500 +28.7% · +74.0 pts vs S&P 500May 15, 2025Jun 9, 202525d
Ro KhannaStockPurchase$1,001 - $15,000+112.1%S&P 500 +42.0% · +70.2 pts vs S&P 500Apr 23, 2025May 12, 202519d
Robert BresnahanStockSale$1,001 - $15,000+119.8%After the saleS&P 500 +53.0% · +66.9 pts vs S&P 500Apr 8, 2025May 8, 202530d
Robert BresnahanStockPurchase$1,001 - $15,000+74.8%S&P 500 +27.9% · +46.9 pts vs S&P 500Feb 25, 2025Mar 27, 202530d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in BIIB, filterable by party, chamber, type and account.

Members of Congress reporting a position

6 members · estimate, as of Oct 21, 2026

6 members report a position (estimated). The largest estimated position is in the $100,001 - $250,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
J. French HillRepublican · House$100,001 - $250,0000.6%
Maria Elvira SalazarRepublican · House$50,001 - $100,0002.8%
Lucy McBathDemocrat · House$15,001 - $50,0000.3%
Gilbert Ray Cisneros, Jr.Democrat · House$15,001 - $50,0000.1%
Robert BresnahanRepublican · House$1,001 - $15,0000.1%
Kevin HernRepublican · House$1,001 - $15,000<0.1%

Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling BIIB?

Across the 4 most recent open-market filings shown here, 1 was a purchase and 3 were sales. 3 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded BIIB?

Maria Elvira Salazar, Kevin Hern, Alan Armstrong, Gilbert Ray Cisneros, Jr., Ro Khanna and Robert Bresnahan disclosed BIIB transactions in the filings shown here.

Which members of Congress hold BIIB?

6 members of Congress report a position in BIIB in the estimate we hold as of Oct 21, 2026. The two largest estimated positions belong to J. French Hill and Maria Elvira Salazar; Lucy McBath holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is BIIB in the S&P 500 or the Nasdaq 100?

Biogen Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are BIIB trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 26 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track